Evaluation of polycystic ovary syndrome pharmacotherapy

Polycystic ovary syndrome (PCOS) is a complex endocrine disorder that affects approximately 5-10 % of women of reproductive age. PCOS can have a significant impact on the quality of life of affected women, contributing to fertility problems and increasing the risk of metabolic and cardiovascular diseases. The aim of this study was to compare and evaluate the effectiveness of indicated 6-month pharmacotherapy in patients with PCOS. Data were collected from the medical records of patients in the gynecological outpatient clinic in Stara Lubovna. A total of 980 patients were enrolled in the study, of which 40 (4 %) were diagnosed with PCOS. At the beginning of the study, the patients were divided into three groups based on the main goal of therapy. The first group consisted of patients aged between 18 and 24 years for whom the primary therapeutic goal was the treatment of menstrual cycle disorders and the treatment of acne (N=13). The second group consisted of patients aged 25 to 35 years who were planning to become pregnant and the therapy was aimed at treating infertility (N= 19). The third group consisted of patients aged 36 years and older who already had a personal history of pregnancy, were not planning another pregnancy, and the therapy was focused on the comprehensive treatment of metabolic syndrome and alopecia (N= 8). To evaluate the effectiveness of the treatment, the mean values of Body Mass Index (BMI) and hormonal profile of the patients were compared by paired t-test (GraphPad Prism 8.3.0), before the start of pharmacotherapy and after 6 months of treatment. Results were considered statistically significant at p < 0.05. Our results confirm the success and efficacy of the indicated pharmacotherapy in all three groups. The selected pharmacotherapy contributed to the modification of the hormonal profile of the patients. The results suggest that PCOS therapy requires complex pharmacotherapy, individual approach and high adherence rate of patients.